Q-omics provides the consensus-scored PRRG2 profile across patient tissues and cancer cell-line models. PRRG2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRRG2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PRRG2 RNA expression shows 16,053 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where PRRG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRRG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRRG2 survival associations across molecular data types. PRRG2 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRRG2 RNA expression–survival associations across cancer types. High PRRG2 expression shows unfavorable associations in ACC, UVM, LGG and MESO, but favorable associations in KIRP and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRRG2 RNA expression.
This table summarizes PRRG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRRG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRRG2 shows lower tumor expression in KIRC, KIRP, KICH and THCA and higher tumor expression in BLCA and UCEC. The KIRC box plot shows higher PRRG2 RNA expression in normal versus tumor tissue (log2 FC = −3.000, t-test p < 0.001).
This table shows molecular features associated with PRRG2 in patient tissues and cancer cell lines. In patient samples, PRRG2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRRG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
